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The aim of this study is to evaluate the neutralization effects of egg yolk immunoglobulin (IgY) and Fab’ 
fragment against lipopolysaccharide (LPS), and identify possible approaches to prevent and treat LPS 
related injuries. Mice with third-degree burns covering 30% of the total body surface and exposed to 
LPS were orally administered with the IgY or Fab’ fragment of egg yolk immunoglobulin at 6, 12, 24 and 
48 h after burning. The mortality rates and circulating levels of LPS, tumor necrosis factor alpha (TNF-α) 
and interleukin-6 (IL-6) were determined. The mortality rate of mice in the IgY-treated groups and Fab’-
treated groups were significantly lower when compared with the control groups (without treatment). The 
levels of LPS, TNF-α and IL-6 in the IgY-treated group and Fab’-treated group were lower than those in 
the control group, and Fab’-treated group posses much lower levels of LPS, TNF-α and IL-6 than IgY-
treated group. The IgY and Fab’ fragment of egg yolk immunoglobulin raised against LPS may be used 
to inhibit and treat tissue injury caused by LPS. IgY technology has significant future opportunities for 
the prevention and treatment of LPS related infectious gastrointestinal diseases in humans and 
animals.  
 





Lipopolysaccharide (LPS), a cytoderm component of 
gram-negative bacteria, also termed endotoxin is asso-
ciated with severe tissue injury and high mortality rates, 
particularly when administered in combination with 
extensive burning. Furthermore, antibiotic therapy increa-
ses the release of LPS and intensifies its injuries. Immu-
noglobulin Y (IgY) is the predominant egg yolk immuno-
globulin in chickens, and is transferred from the serum to 
the yolk to confer passive immunity to the developing 
embryo (Larsson et al., 1993). Egg yolk immunoglobulins 
could be purified simply with low cost and without blood 
collection. Compared with IgG, IgY has some unique 
characteristics because of its phylogenetic distance. It is 
noteworthy that IgY does not cross-react serologically 
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matoid factors (Tini et al., 2002; Lucyna, 2005). IgY also 
shows good bioactivity across a wide pH range of 4.0 to 
9.0 (Lee et al., 2002).  
IgY has been used to prevent and treat infectious 
diseases caused by viruses and bacteria including 
rotaviruses, coronavirus, Yersinia ruckeri, enterotoxigenic 
Escherichia coli, Staphylococcus, Pseudomonas and 
Helicobacter pylori urease B (Tini et al., 2002; Lee, 2002; 
Sarker et al., 2001; Smith et al., 2001; Shin et al., 2002; 
Shin et al., 2003; Nilsson et al., 2007; Zhen et al., 2008). 
Previous studies have shown that the Fab’ fragment of 
egg yolk IgY, which can be obtained by digesting IgY with 
pepsin, can bind to antigens (Akita and Nakai, 1993, 
1993; Carlander et al., 2000). The titer of Fab’ is about 
70% higher than IgY, as determined by ELISA. Therefore, 
the Fab’ fragment appears to enhance antigen neutrali-
zation in tissues because of its greater tissue penetration 
than intact IgY (Panacek et al., 2004). The Fab’ fragment 
was also proposed to be more absorbable from the 
intestinal tract than intact IgY  (Xie  et  al.,  2005).  There- 




Table 1. Mortality rates in mice 6 to 48 h after inducing a third-
degree burn across 30% of the total body surface area and 
oral administration of LPS, without (control group) or with Fab’ 
(Fab’-treated group) and IgY administration (IgY-treated 
group). 
 
Group Time (h) n Mortality (%) 
Control  
group  
6 10 2 (20) 
12 12 4 (33.33) 
24 10 6 (60) 
48 12 8 (66.67) 
Fab’-treated  
group 
6 10 0 (0) 
12 11 2(18.18) 
24 10 2 (20)
a,b
 





6 10 1 (10) 
12 10 2 (20) 
24 10 3 (30)
 a
 





(P < 0.01) versus the control group; 
b





fore, for testing the neutralization effect of anti-LPS IgY or 
Fab’ in vivo, we carried out this study to examine whether 
oral administration of the anti-LPS IgY or Fab’ fragment of 
egg yolk IgY raised against LPS, decreased mortality and 
tissue damage of burned mice exposed to LPS. 
 
 
MATERIALS AND METHODS 
 
Materials and animals  
 
IgY and Fab’ fragment of egg yolk immunoglobulin was prepared 
according to Ma and Zhang (2007). In brief, Roman laying hens 
were immunized with pure LPS mixed with Freund’s Adjuvant, eggs 
were collected before immunization and stored in the refrigerator at 
4°C. IgY against LPS was isolated from yolk of eggs, and then 
purified by water extraction, salt precipitation with ammonium 
sulfate and dialysis. Then, the Fab’ was prepared by the digestion 
of the pepsin. 
Kunming mice weighing 25 ± 1 g were provided by the 
Laboratory Animal Center, Third Military Medical University, China. 
Animals were maintained according to the guidelines of the animal 
ethical committee of China. The experimental procedure was appro-
ved by the Ethical Committee of Southwest Hospital. 
 
 
Animal groups and treatments  
 
Kunming mice were used as the animal model in this study. To 
determine the effect of Fab’ administration on mortality, we 
randomly divided Kunming mice into three groups: a control group, 
an IgY-treated group and a Fab’-treated group. In both groups, after 
withholding food and water for 8 h, the mice under pentobarbital 
anesthesia (60 mg/kg body weight) were shaved on their back, 
weighed and orally administered with 0.2 ml of 10 g/l NaHCO3 
followed by 0.5 ml of LPS (1mg/ml) according to a method 
described by Li and Zhang, (2005) using a remolded syringe 
needle. Then 3% napalm (1 ml) was applied on the shaved skin and 





The total body surface area of the mouse was calculated using 
the formula S = 0.0913 × W2/3, where S (cm2) = total body surface 
area of mouse and W (g) = weight of the mouse. The burn was 
applied over 30% of the total body surface area (TBSA) or S×30%. 
After the burn, the mice were intraperitoneally injected with 2 ml of 
0.9% isotonic NaCl to prevent shock. Povidone-iodine was 
administered on the burned area to prevent infection. All mice were 
returned to their standard cages and provided with food and water.  
In the control group, after establishing the burn, the mice were 
intraperitoneally injected with 0.5 ml 0.9% isotonic NaCl every 6 h. 
In IgY-treated group and Fab’-treated group, the mice were treated 
by orally administering to them 0.5 ml (16 mg/ml) IgY or Fab’ 
(16mg/ml) every 6 h via a remolded syringe needle. The mice in all 
groups were then divided into four subgroups: 6, 12, 24 and 48 h 
after burning with 10 to 12 mice per group. The mortality rates were 
determined in each subgroup at the specified time points, that is, at 
6, 12, 24 and 48 h after burning. After each time point, the existed 
mice were abandoned from the experiment.  
Changes in serum LPS, NF-α or IL-6 levels were assessed in 
other mice, including 10 normal/untreated mice, without undergoing 
burning, 40 mice in a control group, 40 mice in the IgY-treated 
group and 40 mice in the Fab’-treated group. In the normal group, 
the mice continued normal feeding and were not exposed to 
burning. The control and treated mice were prepared as described 
earlier. The mice in the control and treated groups were divided into 
four subgroups (10 mice per group) and the survived mice were 
killed at 6, 12, 24 or 48 h after burning. 
 
 
Measurement of LPS, IL-6 and TNF-α 
 
Blood samples were collected from mice at the appropriate time 
points, centrifuged at 3000 rpm for 10 min to obtain serum and 
stored at -80°C until use. Serum LPS levels were measured using a 
commercially available kit based on the tachypleus amebocyte 
lysate (TAL) technique (Chromogenic TAL endpoint assay kits, 
Chinese Horseshoe Crab Reagent Manufactory Co., Ltd., Xiamen, 
China), and performed in accordance with the manufacturer’s 
instructions (Xia et al., 2002).  
The serum levels of IL-6 and TNF-α were measured using 
relative ELISA kits (e-Bioscience, USA) in accordance with the 
manufacturer’s instructions. References and concentrations were 
calculated by comparison with standard IL-6 or TNF-α solutions 
supplied in the assay kit. 
 
 
Statistic analysis  
 
Data are expressed as means ± standard deviation. SPSS 13.0 
was used for statistical analysis. Statistical significance was eva-
luated by χ2 test for mortality and analysis of variance for LPS, TNF-








The mortality rate of mice in the IgY-treated groups and 
Fab’-treated groups were significantly lower (P < 0.01) 
when compared with the control groups at 24 and 48 h 
after the burn, for the two treated groups, Fab’-treated 
groups had lower mortality rate than IgY-treated groups 
(P < 0.05) at 24 and 48 h, after the burn (Table 1). 






Figure 1. Serum lipopolysaccharide (LPS) levels in mice at 6 to 48 h after inducing 
a third-degree burn across 30% of the total body surface area and oral 
administration of LPS. After inducing the burn, the serum levels of LPS were 
significantly higher (P < 0.01) in the control group (burned mice exposed to LPS but 
without IgY or Fab’ treatment) and in the Fab’-treated or IgY-treated group (burned 
mice exposed to LPS and treated with IgY or Fab’) than in the normal group 
(untreated mice without burning or exposure to LPS). The serum level of LPS was 
significantly lower in the IgY-treated group and Fab’-treated group than in the 
control group (P < 0.01). Fab’-treated group had a lower serum level of LPS than 




Serum LPS levels in different groups 
 
The serum LPS level in each group was detected by a 
chromogenic TAL endpoint assay, as described earlier. 
The level of LPS was lowest in the normal/untreated 
group (mice without burning or administration of LPS) of 
the four groups and was highest in the control group. The 
serum level of LPS was significantly decreased after 
administration of the IgY or Fab’ fragment when 
compared with the control group (P < 0.01) and the Fab’-
treated groups had lower level than IgY-treated groups (P 
< 0.05) (Figure 1). 
 
 
Serum levels of TNF-α and IL-6 
 
The serum TNF-α level increased significantly in the 
control group and in the treated groups in response to the 
burn, and increased to a peak at 24 h after the burn. After 
a further 24 h, the TNF-α levels had slowly decreased, 
but remained significantly higher than in the normal/ 
untreated group throughout the 48-h study period (P < 
0.01). The TNF-α level remained significantly lower in the 
treated groups when compared with the control group (P 
< 0.01) and the Fab’-treated groups had lower level than 
IgY-treated groups (P < 0.05) (Figure 2a). 
Changes in the serum IL-6 level showed a similar 
tendency to the TNF-α level described earlier. After the 
burn, the serum IL-6 level increased markedly in the 
control and treated groups, reaching a peak at 24 h. After 
a further 24 h, the IL-6 levels had begun to decrease, but 
remained at a significantly higher level than in the 
normal/untreated mice throughout the 48-h study period 
(P < 0.01). The IL-6 level remained significantly lower in 
the treated groups when compared with control group (P 
< 0.01) and the Fab’-treated groups had lower level than 





Lipopolysaccharide (LPS) is a component of the 
cytoderm and is released by gram-negative bacterium 
during the growth and death, which can lead to severe 
tissue injury in humans and animals (Michael et al., 
2003). But in healthy animals, LPS could be cleared by 
themselves, and cannot lead to LPS injuries when orally 
administrated a small quantity of LPS. During the initial 
period of time after a burn, particularly, extensive burns 
and excess LPS translocates into the circulation from the 
intestinal tract and the wound, led to tissue damage in the 
intestinal   mucosa   and   whole-body    infection.   These  







Figure 2. Serum TNF-α (a) and IL-6 (b) levels in mice at 6 to 48 h after inducing a 
third-degree burn across 30% of the total body surface area. After inducing the 
burn, the serum levels of TNF-α (a) and IL-6 (b) were significantly higher (P < 0.01) 
in the control group (burned mice exposed to LPS but without IgY or Fab’ 
treatment) and in the Fab-treated group and IgY-treated group (burned mice 
exposed to LPS and treated with Fab’) than in the normal group (untreaed mice 
without burning, exposure to LPS of Fab’ treatment). The serum TNF-α (a) and IL-6 
(b) levels were significantly lower throughout the study period in the IgY-treated 
group and Fab’-treated group than in the control group (P < 0.01). Fab’-treated 




processes may lead to systemic inflammatory response 
syndrome (SIRS), multiple organs dysfunctional syn-
drome (MODS) and death, due to increased intestinal 
permeability and growth of gram-negative bacteria (Niu 
and Wang, 2007). In order to evaluate the neutralization 
effects of IgY and Fab’ fragment in vivo more effectively, 
the burned mice was set as the model in our study. Our 
results showed encouraging results that administration of 
the Fab’ fragment derived from egg yolk immunoglobulin 
raised against LPS reduced the mortality of burned mice 
exposed to LPS. 
The intestinal tract is the largest endotoxin and bacteria 
library. Endotoxins translocate into the circulation from 
the intestinal tract much more easily after the body have 
experienced extensive burning, and activate mono-
nuclear macrophages to promote the release of TNF-α 
and IL-6, which are important mediators of inflammation. 
As a result, activation of the inflammatory cascade 
causes severe cell and tissue injury (Niu and Wang, 







whether neutralization of LPS by early administration of 
the Fab’ fragment of egg yolk IgY raised against LPS 
after extensive burning reduces the uptake of LPS into 
the circulation, inhibits the production of TNF-α and IL-6 
and decreases mortality associated with LPS.  
Egg yolk IgY obtained from hens immunized by 
antigens neutralizes the related antigens specifically with 
high efficiency (Brunda et al., 2006; Sunwoo et al., 2006; 
Paul et al., 2007). As a result, egg yolk immunoglobulins 
have attracted increasing attention because of their 
unique characteristics. They are now widely used for pro-
phylaxis and to treat diseases, particularly infective 
diseases caused by bacteria such as E. coli and 
Salmonella enteritidis, (Zhen et al., 2008; Casswall, 
1999). Therefore, the IgY and Fab’ fragment from egg 
yolk that was specifically raised against LPS was 
obtained.  
Tumor necrosis factor alpha (TNF-α) can activate 
multiple downstream inflammatory pathways to trigger the 
release of pro- and anti-inflammatory mediators, activate 
coagulation and inhibit fibrinolysis. Release of TNF-α can 
be stimulated by LPS, and is the most important host-
derived mediator molecule in the inflammatory cascade 
(Hack et al., 1997; Suffredini et al., 1989). Accordingly, 
reducing the level of circulating TNF-α can limit the 
activation of multiple downstream inflammatory pathways 
and improve survival (Panacek et al., 2004). IL-6 is 
released in response to TNF-α, and plays an important 
role in the inflammatory cascade, and its serum levels are 
thought to be associated with adverse outcome (Thijs 
and Hack, 1995; Casey et al., 1993). In this study, we 
used mice with 30% TBSA third-degree burns and oral 
administration of LPS. After oral administration of the IgY 
or Fab’ fragment, it was found that the mortality of the 
mice decreased significantly when compared with the 
control mice treated with saline. It was also found that the 
serum LPS, IL-6 and TNF-α levels were decreased 
significantly in IgY-treated mice and Fab’-treated mice. 
Based on these results, it is believed that administration 
of the IgY or Fab’ fragment of egg yolk raised against 
LPS decreased the mortality of model mice by neu-
tralizing the circulating LPS. Accordingly, it seems likely 
that the Fab’ fragment was more effective to clear LPS in 
the intestine to inhibit the uptake of LPS into the 
bloodstream, and thus reduce the ability for LPS to 
stimulate inflammatory cells and ultimately limit the 
secretion of inflammatory mediators such as TNF-α and 
IL-6. So, why did the Fab’ fragment gain was more 
effective than intact IgY in this study? We thought the 
Fab’ fragment could enter the circulation through intes-
tinal mucosa like previous report shown (Xie et al., 2005), 
and then neutralize the circulating LPS, but the intact IgY 
did not posses this ability to get through the gastro-
intestinal tract into circulation. Nevertheless, the possi-
bility that there are some direct effects among the Fab’ 
fragment, LPS and inflammatory cells, cannot exclude. 
For example, Fab’ or IgY may stimulate the mononuclear  




phagocytic system to remove LPS via a hitherto unknown 
process. Studies to further investigate these possibilities 





The authors thank the staff of the State Key Laboratory of 
Trauma, Burns and Combined Injury, Southwest Hospital, 
Third Military Medical University for their assistance in 
caring for the animals and providing technical services 





Akita EM, Nakai S (1993). Comparison of four purification methods for 
the production of immunoglobulins from eggs laid by hens immunized 
with an enterotoxigenic E. coli strain. J. Immunol. Methods, 160: 207-
214.  
Akita EM, Nakai S (1993). Production and purification of Fab’ fragment 
fragments from chicken egg yolk immunoglobulin Y (IgY). J. Immunol. 
Methods, 162: 155-164.  
Brunda G, Sashidhar RB, Sarin RK (2006). Use of egg yolk antibody 
(IgY) as an immunoanalytical tool in the detection of Indian cobra 
venom in biological samples of forensic origin. Toxicon. 48:183-194. 
Carlander D, Kollberg H, Wejåker PE, Larsson A (2000). Peroral 
immunotherapy with yolk antibodies for the prevention and treatment 
of enteric infections. Immunol. Res. 21: 1-6.  
Casey LC, Balk RA, Bone RC (1993). Plasma cytokine and endotoxin 
levels correlate with survival in patients with the sepsis syndrome. 
Ann. Int. Med. 119:771-778. 
Casswall T (1999). Passive immunization as therapy for gastrointestinal 
infections in children. Doctoral Thesis Reproprint AB (ISBN-91-628-
3862-8), Stockholm, Sweden: Karolinska Institute.  
Hack CE, Aarden LA, Thijs LG (1997). Role of cytokines in sepsis. Adv. 
Immunol. 66: 101-195. 
Larsson A, Bålöw RM, Lindahl TL, Forsberg PO (1993). Chicken 
antibodies: taking advantage of evolution-a review. Poult. Sci. 72: 
1807-812. 
Lee KA, Chang SK, Lee YJ, Lee JH, Koo NS (2002). Acid stability of 
anti-Helicobacter pylori IgY in aqueous polyol solution. J. Biochem. 
Mol. Biol. 35: 488-493.  
Li Q, Zhang YP (2005). Effects of specific egg yolk immunoglobulin 
(IgY) on burned mice with intestinal endotoxemia. Chin. J. Trauma, 
10: 773-774. 
Lucyna C (2005). DNA-designed avian IgY antibodies: novel tools for 
research, diagnostics and therapy. J. Clin. Virol. 34 Suppl 1: S70-74. 
Ma S, Zhang Y (2007). Production of Fab’of the chicken egg yolk 
antibody against lipopolysaccharide. Immunol. J. 23: 219-221. 
Michael T, Madigan JM, Martinko JP (2003). Brock biology of 
microorganisms (ISBN 84-205-3679-2). Madrid, Spain: Pearson-
Prentice Hall.  
Nilsson E, Amini A, Wretlind B, Larsson A (2007). Pseudomonas 
aeruginosa infections are prevented in cystic fibrosis patients by 
avian antibodies binding Pseudomonas aeruginosa flagellin. J 
Chromatogr. B Analyt. Technol. Biomed. Life Sci. 856: 75-80. 
Niu H, Wang B (2007). Intestinal mucosal barrier and iIts function. 
Anatomy Clinics, 12: 138-140.  
Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, 
MacArthur RD, Miller M, Barchuk WT, Fischkoff S, Kaul M, Teoh L, 
Van Meter L, Daum L, Lemeshow S, Hicklin G, Doig C (2004). 
Efficacy and safety of the monoclonal anti-tumor necrosis factor 
antibody F(ab')2 fragment afelimomab in patients with severe sepsis 
and elevated interleukin-6 levels. Crit. Care Med. 32: 2173-2182. 
Paul K, Manjula J, Deepa EP, Selvanayagam ZE, Ganesh KA, Subba 
Rao PV (2007). Anti-Echis carinatus venom antibodies from chicken 
egg yolk:  isolation,  purification  and  neutralization  efficacy. Toxicon.  




50: 893-900.  
Sarker SA, Casswall TH, Juneja LR, Hoq E, Hossain I, Fuchs GJ, 
Hammarstrom L  (2001). Randomized, placebo-controlled, clinical 
trial of hyperimmunized chicken egg yolk immunoglobulin in children 
with rotavirus diarrhea. J. Pediatr. Gastroenterol. Nutr. 32: 19-25.  
Shin JH, Nam SW, Kim JT, Yoon JB, Bang WG, Roe IH (2003). 
Identification of immunodominant Helicobacter pylori proteins with 
reactivity to H. pylori-specific egg-yolk immunoglobulin. J. Med. 
Microbiol. 52: 217-222. 
Shin JH, Yang M, Nam SW, Kim JT, Myung NH, Bang WG, et al (2002). 
Use of egg yolk-derived immunoglobulin as an alternative to antibiotic 
treatment for control of Helicobacter pylori infection. Clin. Diagn. Lab. 
Immunol. 9: 1061-1066. 
Smith DJ, King WF, Godiska R (2001). Passive transfer of 
immunoglobulin Y antibody to Streptococcus mutans glucan binding 
protein B can confer protection against experimental dental caries. 
Infect Immun. 69: 3135-3142. 
Suffredini AF, Harpel PC, Parrillo JE (1989). Promotion and subsequent 
inhibition of plasminogen activation after administration of 

























































Sunwoo HH, Wang WW, Sim JS (2006). Detection of Escherichia coli 
O157:H7 using chicken immunoglobulin Y. Immunol. Lett. 106: 191-
193. 
Thijs LG, Hack CE (1995). Time-course of cytokine levels in sepsis. 
Intensive Care Med. 21: S258-263.   
Tini M, Jewell UR, Camenisch G, Chilov D, Gassmann M (2002). 
Generation and application of chicken egg-yolk antibodies. Comp. 
Biochem. Physiol. A Mol. Integr. Physiol. 131: 569-574. 
Xia PY, Zheng J, Zhou H, Pan WD, Qin XJ, Xiao GX (2002). 
Relationship between lymphocyte apoptosis and endotoxin 
translocation after thermal injury in rats. World J. Gastroenterol. 8: 
546-550. 
Xie X, Zhou X, Wang F (2005). Research Progress on Yolk Antibody of 
Vaccinated Hens. China Poult. 27: 41-42. 
Zhen YH, Jin LJ, Guo J, Li XY, Lu YN, Chen J, Xu YP (2008). 
Characterization of specific egg yolk immunoglobulin (IgY) against 
mastitis-causing Escherichia coli. Vet. Microbiol. 130: 126-133.  
 
 
 
